Table 1

Subjects’ characteristics

Patients with an initiation/increased dose of ICS between two visitsPatients with a cessation/decreased dose of ICS between two visitsPatients with no ICS or a stable dose of ICS between two visitsP value
n1016063
Time between the two visits, years1.0 (0.5–2.6)1.5 (0.9–2.6)2.0 (0.7–3.8)0.045
Women, n (%)56 (55)33 (55)41 (65)0.41
Age, years53 (40–63)51 (37–62)53 (44–66)0.42
BMI, kg/m²26.3±5.126.4±4.726.8±4.90.83
Atopy, n (%)52 (51)35 (58)32 (51)0.64
Age of asthma onset, years41 (16–57)31 (8–53)46 (27–55)0.12
Smoking status, n (%)0.22
 Non-smokers53 (52)31 (52)32 (51)
 Current smokers11 (11)11 (18)15 (24)
 Ex-smokers37 (37)18 (30)16 (25)
Patients with EA at first visit, n (%)79 (78)22 (37)26 (41)<0.001
Variation of ICS dose*800 (400–1200)900 (500–1200)0
  • *ICS dose expressed in beclomethasone chlorofluorocarbon (CFC) equivalents.

  • BMI, body mass index; EA, eosinophilic asthma; ICS, inhaled corticosteroid.